Onkologie. 2013:7(1):13-16
Bisphosphonates in treating myeloma bone disease
- Interní hematologická a onkologická klinika LF, MU, Brno-Bohunice
The attention devoted to the effect of bisphosphonates in treating bone disease is particularly focused on bone disease in breast and
prostate cancer and only exceptionally in other solid tumours. Every year, new information on bisphosphonates is presented at the
ZENITH Meeting. In recent years, the meetings’ topics have centred around evidence of antitumour activity of bisphosphonates and
their potential use in adjuvant therapy. Surprisingly, this year’s topic of the ZENITH Meeting was focused on bone disease in malignant
myeloma, i.e. an area more likely debated by haematologists. In March 2012, 150 bisphosphonates experts from all over the world met
in Munich, Germany, to discuss the current role of bisphosphonates in treating bone disease in malignant myeloma. The majority of the
papers presented new data in an effort to synthesise the current status in this area. This paper provides a selection of the papers presented.
Keywords: myeloma, bisphosphonates, bone disease
Published: February 1, 2013 Show citation
